THE RNS SYSTEM

New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life

Retrieved on: 
Monday, July 27, 2020

The RNS System has been shown to dramatically reduce seizures and improve quality of life for people living with refractory epilepsy.

Key Points: 
  • The RNS System has been shown to dramatically reduce seizures and improve quality of life for people living with refractory epilepsy.
  • Real-world data from a multicenter clinical study of the RNS System were published in Epilepsia, demonstrating seizure reductions not seen with any other neuromodulation system for refractory focal epilepsy.
  • At three or more years, patients experienced an unprecedented 82% median reduction in seizure frequencythe highest reported for any neuromodulation system.
  • Physicians reported that 75% of patients who received the RNS System were much improved or very much improved in their functioning at most recent follow up.

NeuroPace Announces Michael Favet as CEO

Retrieved on: 
Wednesday, July 24, 2019

NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the appointment of Michael Favet as Chief Executive Officer.

Key Points: 
  • NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the appointment of Michael Favet as Chief Executive Officer.
  • Frank Fischer, after 20 years serving as CEO, continues with NeuroPace as Chairman of the Board of Directors.
  • Mr. Favet has served on the NeuroPace board since 2016, and has been the acting Chief Commercial Officer since 2018.
  • Im thrilled to build upon what he has created and to lead NeuroPace during this exciting period of commercial growth, said Mr. Favet.